Back to Mirati Therapeutics


Manufactured By:
Mirati Therapeutics
9393 Towne Center Drive
Suite 200
San Diego CA 92121
United States


Adagrasib (MRTX849) is a potent, highly selective and orally available small molecule inhibitor of a form of KRAS that harbors an oncogenic substitution mutation (G12C). KRAS G12C is a well-validated driver mutation present in approximately 14% of NSCLC adenocarcinoma patients and 5% of CRC patients. 

Adagrasib has demonstrated broad-spectrum antitumor activity across a panel of KRAS G12C-positive patient- and cell-derived in vivo tumor models, including complete tumor regression in a subset of these models. MRTX849 is now in the clinic and has the potential to provide a long-awaited targeted therapy option for patients exhibiting a KRAS driver mutation.

Please note, Mirati does not currently provide access to adagrasib outside of enrollment in an adagrasib clinical trial. 

For information on Mirati clinical trials, please visit or visit Mirati Clinical Trials.